Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Trial Evaluating Cardiovascular Outcomes with
Sitagliptin (TECOS) of Mercks DPP-4 inhibitor, JANUVIA
(sitagliptin), achieved its primary endpoint of non-inferiority for the
composite cardiovascular (CV) endpoint. Among secondary endpoints, there
was no increase in hospitalization for heart failure in the sitagliptin
group versus placebo.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestor:Joe Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more